Quantcast
Last updated on April 17, 2014 at 12:35 EDT

Latest Rhinology Stories

2009-03-23 05:00:00

This exciting clinical study news is the best news that we have been waiting on for the past four years to prove the deposition of the medication through Sinus Dynamics. WESTLAKE VILLAGE, Calif., March 23 /PRNewswire/ -- Most ENTs and physicians who have prescribed Sinus Dynamics have always asked if it would be better to have a clinical study done on the amount of medication deposited and penetrated into the sinuses. Now this fantastic news and clinical study proves the SINUS DYNAMICS...

2009-03-18 12:07:00

Saint Joseph Hospital Among the First to Offer New Surgical Treatment Approach CHICAGO, March 18 /PRNewswire/ -- After three years of suffering from congestion and several months of trying a steroid nasal spray, Chicago resident Matt Minella, 31, opted for a surgical procedure to help him breathe better through his nose. Within days of the procedure, Minella was back to work and running again thanks to a new endoscopic balloon device called the Relieva Stratus(TM) Microflow Spacer. The...

2009-03-17 09:51:00

Eliminates Need for Cadavers and Accelerates Physician Training GREAT BARRINGTON, Mass., March 17 /PRNewswire/ -- The Chamberlain Group, maker of anatomically accurate surgical training models, is improving how ENT physicians are trained using their new Maxillary Clinical Sinus Trainer. This innovative technology was recently designed for Minnesota-based Entellus Medical to train ENT surgeons on their new FinESS(TM) Sinus Treatment, a less-invasive treatment that breaks the cycle of chronic...

2009-01-15 07:00:00

ASTEPRO(TM) (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, N.J., Jan. 15 /PRNewswire/ -- This allergy season, a new medication is available to manage the symptoms of seasonal allergic rhinitis, a condition that impacts as many as 40 million people in the United States. ASTEPRO Nasal Spray contains azelastine in a unique vehicle formulated for enhanced patient benefits. Azelastine is the active ingredient in ASTELIN(R) (azelastine hydrochloride), a leading...

2008-12-16 07:00:00

HARBIN, China, Dec. 16 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully obtained the production approval from the State Food and Drug Administration (SFDA) in China for two additional drugs: Sodium Cromoglicate Eye Drops for the treatment of allergic...

2008-11-07 09:00:05

Morria Biopharmaceuticals, a developer of anti-inflammatory drugs, has announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The nasal allergen challenge study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared with both placebo (arm 1) and an intranasal steroid Rhinocort (as a positive control, arm 2)....

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared...

2008-10-30 12:00:21

Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort as the steroid comparator arm. A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory mediators or markers in the...

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation. Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute...


Latest Rhinology Reference Libraries

Politzerization
2012-12-31 12:28:34

In 1861 Adam Politzer of Vienna spent much time studying the air movement in the Eustachian tubes and the ear canal. He would measure the air movement by attaching a manometer, a very large gauge, to the ear canal and the pharynx. He developed an apparatus known as the Politzer bag in 1863 which is a less invasive way to clear the Eustachian tubes. Procedure Politzerization, also known as the Politzer maneuver, is a medical procedure which inserts air in the middle ear while the patient...

More Articles (1 articles) »